Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)

Authors :: Martin S. Tallman
Dan Douer
David A. Scheinberg
Suzanne Chanel
Mark G. Frattini
Jae Hong Park
Peter Maslak
Andres A. Gutierrez
Tao Dao
Joseph G. Jurcic
Laura Katz
Yvette Bernal
Rong Zhang
Todd L. Rosenblat
Raajit K. Rampal
Source :: Journal of Clinical Oncology. 34:7005-7005
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 7005Background: An NCI consensus study on prioritization of cancer antigens identified WT1 as the #1 ranked immunotherapy target. We previously reported on the safety, immunogenicity, and prolonged...

Tools